Samalin Investment Counsel LLC Takes Position in Nkarta, Inc. (NASDAQ:NKTX)

Samalin Investment Counsel LLC purchased a new stake in Nkarta, Inc. (NASDAQ:NKTX) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 84,575 shares of the company’s stock, valued at approximately $211,000.

Other institutional investors have also made changes to their positions in the company. Wasatch Advisors LP increased its holdings in shares of Nkarta by 31.7% in the 3rd quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock valued at $8,293,000 after acquiring an additional 442,125 shares during the last quarter. Geode Capital Management LLC grew its stake in Nkarta by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock worth $5,294,000 after buying an additional 33,927 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Nkarta by 252.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,063,362 shares of the company’s stock worth $4,806,000 after buying an additional 761,349 shares during the last quarter. Franklin Resources Inc. bought a new position in Nkarta during the 3rd quarter worth $151,000. Finally, FMR LLC grew its stake in Nkarta by 97.1% during the 3rd quarter. FMR LLC now owns 133,149 shares of the company’s stock worth $602,000 after buying an additional 65,600 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors.

Nkarta Price Performance

Shares of NKTX opened at $1.50 on Monday. The company has a market cap of $105.85 million, a P/E ratio of -0.80 and a beta of 0.90. The stock has a fifty day moving average price of $2.06 and a 200 day moving average price of $2.96. Nkarta, Inc. has a 12 month low of $1.44 and a 12 month high of $11.84.

Insider Buying and Selling

In related news, CEO Paul J. Hastings sold 17,378 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the transaction, the chief executive officer now directly owns 319,859 shares in the company, valued at $703,689.80. This represents a 5.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.70% of the stock is owned by company insiders.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.